Biondo Investment Advisors LLC Purchases New Position in TransMedics Group, Inc. $TMDX

Biondo Investment Advisors LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 44,155 shares of the company's stock, valued at approximately $2,933,000. Biondo Investment Advisors LLC owned approximately 0.13% of TransMedics Group as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Emerald Investment Advisers LLC bought a new stake in TransMedics Group in the second quarter worth approximately $2,023,000. EP Wealth Advisors LLC bought a new position in shares of TransMedics Group during the 2nd quarter valued at $1,023,000. Keebeck Wealth Management bought a new position in shares of TransMedics Group during the 2nd quarter valued at $387,000. Allworth Financial LP bought a new position in shares of TransMedics Group during the 2nd quarter valued at $167,000. Finally, Silvant Capital Management LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter valued at $26,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on TMDX shares. Wall Street Zen cut shares of TransMedics Group from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. UBS Group cut their target price on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a report on Wednesday, August 5th. Needham & Company LLC decreased their price target on TransMedics Group from $142.00 to $106.00 and set a "buy" rating for the company in a research note on Monday, August 3rd. Canaccord Genuity Group reiterated a "buy" rating and set a $124.00 price target on shares of TransMedics Group in a research note on Tuesday, June 30th. Finally, Stifel Nicolaus increased their price objective on TransMedics Group from $75.00 to $80.00 and gave the company a "hold" rating in a report on Thursday, June 18th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $124.18.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $94.77 on Monday. The firm has a market capitalization of $3.28 billion, a PE ratio of 24.36 and a beta of 1.90. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The firm's fifty day simple moving average is $77.49 and its 200 day simple moving average is $95.05.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). The firm had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm's revenue was up 20.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.92 EPS. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1.47 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the business's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares of the company's stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company's stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source